Register for Zoom In on Dementia & Alzheimer’s: Clinical Research
Register for Zoom In on Dementia & Alzheimer’s: Clinical Research
Register to join our free virtual program and engage in a live conversation with experts in the field.
TOPIC
The SPRING Trial: Targeting Gum Bacteria in Alzheimer’s
DATE
Thursday, April 2, 2026
TIME
1 pm ET (please adjust for your time zone)
SPEAKER(S)
Michael J. Detke, MD, PhD
Emerging science suggests that the bacteria P. gingivalis—which is associated with gum disease—may play a role in Alzheimer’s disease. In this episode, Dr. Michael J. Detke of Lighthouse Pharma explains the SPRING clinical trial and how the investigational oral drug LHP588 is being studied to reduce bacteria-related brain damage. He also outlines who may qualify and what participation involves for individuals with mild to moderate Alzheimer’s and their caregivers.
Registration is closed for the April 2nd program “The SPRING Trial: Targeting Gum Bacteria in Alzheimer’s”
Watch Past Episodes
The SPRING Trial: Targeting Gum Bacteria in Alzheimer’s
Dr. Michael J. Detke of Lighthouse Pharma explains the SPRING clinical trial and how the investigational oral drug LHP588 is being studied to reduce bacteria-related brain damage.
Is It Alzheimer’s? Recognizing Early Signs & Symptoms
Behavioral neurologist Dr. Sharon Cohen explains the early signs and symptoms of Alzheimer’s disease, medical conditions that can mimic dementia, and how to start a conversation with your doctor.
Alzheimer’s Clinical Trials 2026: An Insider’s Look with Dr. Jeffrey Cummings
Join Dr. Jeffrey Cummings as he shares an insider’s overview of the evolving Alzheimer’s treatment development pipeline.
Understanding Your APOE Status: Genetics and Alzheimer’s Risk
About 25% of people carry one copy of the APOE4 gene, the strongest genetic risk factor for developing Alzheimer’s. Dr. Eric M. Reiman explains what genetic testing can—and cannot—tell you, including why APOE4 signals increased risk but does not mean a definite Alzheimer’s diagnosis.
Leqembi and Kisunla: Your Questions Answered
A leading neurologist answers your most common questions about what Leqembi and Kisunla can realistically do, including effectiveness, safety, eligibility, infusion logistics, cost, and access.
The AHEAD Study: Can Alzheimer’s Be Prevented or Slowed Before Symptoms Begin?
Join Dr. Joshua Grill as he shares details about the AHEAD Study.
The Next Generation of Alzheimer’s Treatments
Behavioral neurologist Dr. Marwan Sabbagh explains emerging Alzheimer’s therapeutics now in late-stage clinical development.
The Gut Microbiome and Alzheimer’s Disease: Understanding the Connection
Join Dr. Beau Ances of Washington University in St. Louis to learn about the emerging science linking gut health and brain health.
U.S. POINTER Study Update: Lifestyle Program Significantly Improves Cognition in Older Adults
Can everyday lifestyle choices really protect your memory? Dr. Laura Baker, professor at Wake Forest University School of Medicine, will share results from the groundbreaking U.S. POINTER trial—the largest study of its kind to test how lifestyle changes impact brain health.
Zoom In on Dementia & Alzheimer’s is supported in part through sponsorships from:
